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ABSTRACT
Objective To summarise the benefits and harms of
treatments for women with gestational diabetes mellitus.
Design Systematic review and meta-analysis of
randomised controlled trials.
Data sources Embase, Medline, AMED, BIOSIS, CCMed,
CDMS, CDSR, CENTRAL, CINAHL, DARE, HTA, NHS EED,
Heclinet, SciSearch, several publishers’ databases, and
reference lists of relevant secondary literature up to
October 2009.
Review methods Included studies were randomised
controlled trials of specific treatment for gestational
diabetes compared with usual care or “intensified”
compared with “less intensified” specific treatment.
Results Five randomised controlled trials matched the
inclusion criteria for specific versus usual treatment. All
studies used a two step approach with a 50 g glucose
challenge test or screening for risk factors, or both, and a
subsequent 75 g or 100 g oral glucose tolerance test.
Meta-analyses did not show significant differences for
most single end points judged to be of direct clinical
importance. In women specifically treated for gestational
diabetes, shoulder dystocia was significantly less
common (odds ratio 0.40, 95% confidence interval 0.21
to 0.75), and one randomised controlled trial reported a
significant reduction of pre-eclampsia (2.5 v 5.5%,
P=0.02). For the surrogate end point of large for
gestational age infants, the odds ratio was 0.48 (0.38 to
0.62). In the 13 randomised controlled trials of different
intensities of specific treatments, meta-analysis showed
a significant reduction of shoulder dystocia in women
with more intensive treatment (0.31, 0.14 to 0.70).
Conclusions Treatment for gestational diabetes,
consisting of treatment to lower blood glucose
concentration alone or with special obstetric care, seems
to lower the risk for some perinatal complications.
Decisions regarding treatment should take into account
thattheevidenceofbenefitisderivedfromtrialsforwhich
women were selected with a two step strategy (glucose
challenge test/screening for risk factors and oral glucose
tolerance test).
INTRODUCTION
Gestational diabetes mellitus, defined as “carbohy-
drate intolerance of varying degrees of severity with
onset or first recognition during pregnancy,”
1 is asso-
ciated with an increased risk of complications for
mother and child during pregnancy and birth.
2
Among those complications are shoulder dystocia
and birth injuries, neonatal hyperbilirubinaemia,
hypoglycaemia,respiratorydistresssyndrome,caesar-
ean section, and pre-eclampsia.
2 Fetal macrosomia is
associated with gestational diabetes
2 and is a surrogate
for many of the complications. Epidemiological
research suggests that women who have gestational
diabetes have an increased risk of type 2 diabetes
later in life.
3
Diagnosisofgestationaldiabetesiscommonlybased
on the results of oral glucose tolerance tests. Depend-
ing on cut-off values, ethnicity, and other factors, the
prevalence in the US is estimated to be 7%
4 and is
thought to be increasing.
5
Specific treatment, consisting of treatment to lower
glucose concentrations and special obstetric manage-
ment, is recommended to reduce the risk to mothers
and infants during pregnancy and later in life. But it
remains controversial which outcomes can be influ-
enced. Also, it is still unclear which affected women,
and their offspring, with what degree of maternal car-
bohydrate intolerance, will benefit from treatment.
This uncertainty is reflected in the fact that various
screening strategies and diagnostic criteria are used to
identify women with gestational diabetes mellitus.
6-10
The main options for diagnosis are a one step oral
glucose tolerance test (either taking measurements at
fasting, one and/or two hours after 75 g glucose, or at
fasting, one, two, and three hours after 100 g) or a two
step strategy. This entails screening with either a list of
risk factors or a one hour 50 g glucose challenge test
and then an oral glucose tolerance test only in those
women with positive results. Women’s preferences
have not been systematically studied.
Weconductedasystematicreviewtodeterminewhat
possible beneficial effects can be achieved by specific
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their offspring will benefit from such treatment. We
included treatments aimed at lowering blood glucose
concentration with or without specific obstetric inter-
ventions, such as routine induction of labour. We gave
special consideration to the selection strategies used to
recruit women for the intervention trials.
METHODS
Our main aim wasto assess the effects of specific inter-
ventions for gestational diabetes on the risk of preg-
nancy, perinatal, and long term complications in
pregnant women with carbohydrate intolerance iden-
tified by a glucose tolerance test. Benefit from treat-
ment in these women is a prerequisite for
effectiveness of a screening programme for gestational
diabetes.
Inclusion and exclusion criteria
To be eligible for inclusion in our systematic review,
studies had to examine specific treatment for gesta-
tional diabetes compared with usual care or “intensi-
fied” specific treatment with “less intensified” specific
care, had to include pregnant women with an impair-
ment of their glucose tolerance (based on the results of
an oral glucose tolerance test), and had to report on at
least one outcomeof interest (see below). We included
only randomised trials.
As one would not expect to see an effect of an inter-
vention in studies aimed at non-inferiority or equiva-
lence for the head-to-head treatment comparisons, we
excludedtrialsiftherewasnocleardifferenceininten-
sity (for example, additional treatment, earlier treat-
ment, earlier and more frequent treatment, lower
target concentrations for blood glucose, special neo-
natal care, etc) of interventions planned.
Search
We carried out a literature search using Embase,
Embase Alert, Medline, AMED, BIOSIS, BIOS
IS Preview, CCMed, CDMS, CDSR, CENTRAL,
CINAHL, DARE, HTA, NHS EED, Heclinet, Jour-
nals@OvidFullText,SciSearch,publishers’databases
(Hogrefe, Karger, Kluwer, Krause and Pachernegg,
Springer, Thieme), and the reference lists of relevant
secondary literature up to October 2009.
Multiple teams of two reviewers (AS, KH, KJ, EM,
and/or additional researchers) independently
screenedthetitle,abstract,andkeywordsofeachrefer-
ence identified by the search and applied the inclusion
and exclusion criteria. For potentially eligible refer-
ences the same procedure was applied to full text arti-
cles. Differences between reviewers were resolved by
discussion or a third reviewer (AS, KH, KJ, EM, UP,
KK). Data on quality, patients’ characteristics, inter-
ventions, and relevant outcomes were independently
abstracted by two reviewers (AS, KH, KJ, EM, UP,
and/or KK).
Assessmentofriskofbiaswasbasedontheadequacy
of randomisation, allocation concealment, blinding of
outcome assessors, comparability of women in the dif-
ferent intervention groups for prognostically relevant
factors at baseline, and handling of missing values
(suchaswithdrawalsanddropouts).Asgestationaldia-
betes is treated by complex interventions that are not
amenable to blinding, we did not consider lack of
blinding of patients and study staff to be a major flaw.
Differences between reviewers were resolved by dis-
cussion or a third reviewer (RB).
Outcomes of interest
The interventions were compared for their effect on
several outcomes relevant to patients: maternal and
perinatal mortality, birth injuries, mode of delivery,
shoulder dystocia, pre-eclampsia and eclampsia, neo-
natal hypoglycaemia, hyperbilirubinaemia and other
metabolic disturbances needing an intervention,
respiratory distress needing respiration, admission to
neonatal intensive care, length of hospital stay, aspects
of quality of life, and adverse events. Surrogate para-
meters considered included macrosomia or large for
gestationalageinfants,smallforgestationalageinfants,
preterm birth, Apgar score, development of obesity in
the child, gestational hypertension, and development
of type 2 diabetes later in the woman’s life.
Statistical analysis
When clinically and statistically appropriate, we com-
binedresultsfromsinglestudiesbymeta-analysisusing
arandomeffectsmodelbasedonthemethodofDerSi-
monian and Laird.
11 The effects measure was the odds
ratio. In the case of rare events(<1%) we used the Peto
one step method to pool odds ratios.
12 Heterogeneity
betweentrialswasassessedwithχ
2testandtheI
2statis-
tic, which describes the percentage of the variability in
effect estimates caused by heterogeneity.
1314 In the
case of substantial heterogeneity (P<0.2)
15 no pooled
estimate was provided.
The methods, the inclusion and exclusion criteria,
and the outcomes of interest were described in a pre-
published protocol.
16
Potentially relevant reports identified and screened for retrieval (n=2449)
Reports retrieved for more detailed evaluation (n=108)
Potentially appropriate controlled trials (n=27 trials/41 reports)
Randomised controlled trials included in meta-analyses (n=18)
Reports excluded on basis of title, abstract review (n=2341)
Reports excluded after detailed review (n=67):
  Not gestational diabetes (n=10)
  Control intervention not usual care or specific intervention with lower intensity (n=35)
  No controlled trial (n=13)
  Reported none of the outcomes of interest (n=6)         
  Abstract (n=3)
Trials excluded from meta-analysis (n=9):
  Not randomised controlled trial (n=8)
  Discrepancies between reports (n=1)
Fig 1 | Flowchart of article selection in trial
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Figure 1 shows the number of trials identified and
includedwithreasonsforexclusion.Theidentifiedstu-
dies were allocated to one of two study pools based on
thecontroltreatment.PoolAcontainedallrandomised
trials of specific treatment for gestational diabetes mel-
litus compared with usual care. Pool B contained all
randomised trials that compared specific treatments of
different intensities. The comparison with usual care
enabled direct inferences and effect sizes to be drawn.
Pool B allowed for indirect conclusions, including the
evaluation of dose-response relations.
Pool A
Five randomised trials matched the inclusion criteria
for specific treatment for gestational diabetes com-
paredwithusualcare(table 1).
17-23Thetrialswerepub-
lished from 1966 to 2009 and included 2999 women.
Intheinterventiongroupsallpregnantwomenmea-
sured their own glucose concentrations and were trea-
ted with diet alone or additional insulin treatment if
blood glucose concentrations exceeded prespecified
targets. All studies used a two step approach with a
50 g glucose challenge test or check of risk factors, or
both, and a subsequent 75 g or 100 g oral glucose tol-
erancetest.Bonomoetalincludedwomenwithaposi-
tive result on the glucose challenge test but a negative
result to the oral glucose tolerance test
17; all other stu-
dies required a positive glucose challenge test and a
positive oral glucose tolerance test for inclusion.
Table 1 shows further details of study characteristics.
Pool B
Fourteen studies that compared different intensities of
specific treatments fulfilled the inclusion criteria.
24-43
We excluded the study by Yang et al
4243 because dis-
crepanciesbetweenpublicationsmeantthatdatainter-
pretation was impossible. This left 13 trials to include
in the different meta-analyses. Table 2 gives details of
thediagnosisandtreatmentinthesestudiesandfurther
details on study characteristics.
Bias
In pool A the risk for bias was judged to be low for
Crowther et al
19 and Landon et al
21 and high for the
three remaining trials (table 3). In pool B, the risk for
bias was judged to be low in two studies,
3739 and high
for the remaining trials (table 3).
Table 1 |Characteristics of studies included in pool A: specific treatment for gestational diabetes mellitus versus usual care. All studies took place in
hospital outpatient facilities
No Diagnosis Intervention
Mean (SD) age
(years)
Mean (SD) gestation at
study entry (weeks) Mean (SD) BMI Ethnicity (%)
Bonomo 2005
17 (Italy)
Intervention 150 2 steps: risk factors present,
positiveon50gglucosechallenge*;
negative on 100 g oral glucose
tolerance test†
Diet 31 (5) NA 23 (4) All white
Control 150 Usual care 31 (5) NA 23 (5) All white
Crowther 2005
18-20 (Australia)
Intervention 490 2 steps: risk factors present or
positive result on 50 g glucose
challenge*; positive result on 75 g
oral glucose tolerance test§
Diet/insulin 31 (5) 29 (28-30)‡ 27 (23-31)‡ White 73, Asian 19, other 9
Control 510 Usual care 30 (6) 29 (28-30)‡ 26 (23-31)‡ White 78, Asian 14, other 8
Landon 2009
21 (USA)
Intervention 485
2 steps: positive on 50 g glucose
challenge, positive on 100 g oral
glucose tolerance test¶
Diet/insulin 29 (6) 29 (2) 30 (5) White 25, Latin-American 58,
Afro-American 12, Asian 5, other 1
Control 473 Usual care 29 (6) 29 (2) 30 (5) White 25, Latin-American 56,
Afro-American 11, Asian 6, other 2
Langer 1989
22 (USA)
Intervention 63
2 steps: positive on 50 g glucose
challenge**, positive on 100 g oral
glucose tolerance test††
Diet/insulin 31 (5) 31 (3) NA‡‡ White 36, Latin-American 33,
Afro-American 30
Control 63 Usual care 28 (6) 31 (3) NA‡‡ White 33, Latin-American 33,
Afro-American 33
O’Sullivan 1966
23 (USA)
Intervention 307 2 steps: risk factors present or
positive on 50 g glucose
challenge**, positive on 100 g oral
glucose tolerance test¶¶
Diet and
insulin
30 (NA) NA NA NA
Control 308 Usual care 31 (NA) NA NA NA
BMI=body mass index; NA=not applicable/not available.
*Positive if blood glucose ≥7.8 mmol/l one hour after 50 g glucose challenge.
†Carpenter-Coustan criteria. Positive if ≥2 values are ≥5.3 mmol/l fasting blood glucose, ≥10.0 mmol/l blood glucose at one hour, ≥8.7 mmol/l at two hours, ≥7.8 mmol/l at three hours.
‡Median (interquartile range).
§WHO criteria. Positive if fasting blood glucose <7.8 mmol/l and blood glucose 7.8-11.0 mmol/l at two hours (from 1998 ≥7.0 mmol/l and/or 7.8-11.0 mmol/l, respectively).
¶For 50 g challenge, positive if blood glucose 7.5-11.1 mmol/l at one hour. For 100 g tolerance text, positive if fasting blood glucose <5.3 mmol/l and ≥2 values are ≥10.0 mmol/l blood
glucose at one hour, ≥8.6 mmol/l at two hours, ≥7.8 mmol/l at three hours.
**Positive if plasma glucose >7.2 mmol/l one hour after 50 g glucose challenge.
††NDDG criteria. Positive if ≥2 values ≥5.8 mmol/l fasting blood glucose, ≥10.6 mmol/l blood glucose at one hour, ≥9.2 mmol/l at two hours, ≥8.1 mmol/l at three hours.
‡‡38% of women in intervention group and 41% of women in control group had BMI ≥27.
§§Positive if ≥2 values ≥6.1 mmol/l fasting blood glucose, ≥9.4 mmol/l blood glucose at one hour, ≥6.6 mmol/l at two hours, ≥6.1 mmol/l at three hours.
¶¶Positive if ≥2 values ≥6.1 mmol/l fasting blood glucose, ≥9,4 mmol/l blood glucose at one hour, ≥6,7 mmol/l at two hours, ≥6,1 mmol/l at three hours.
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None of the trial specifically reported on maternal
deaths. There were no significant differences between
specific treatment and usual care in three
171922 of the
four studies that reported caesarean sections (table 4).
Landon et al reported a significantly lower rate of cae-
sareansectionswithspecificinterventions.
21Themeta-
analysis,whichincludedresultsfromallfour trials,did
not show a significant difference, the odds ratio being
0.86 (95% confidence interval 0.72 to 1.02) (fig 2). In
thestudyofLandonetal12of476women(2.5%)inthe
intervention group and 25 of 455 women (5.5%) in the
usual care group developed pre-eclampsia (P=0.02).
21
Only Crowther et al
19 and Landon et al
21 reported on
shoulder dystocia. The pooled analysis of both studies
yielded a significant difference in favour of the inter-
vention group (0.40, 0.21 to 0.75; fig 2).
Only one trial reported on long term complications
in the mother. O’Sullivan et al reported that 35% of
women in the specific treatment and 36% of women
in the usual care group developed diabetes within
16 years after delivery (table 4).
23 The difference was
not significant. Other long term outcomes were not
reported.
Three trials provided information on perinatal or
neonatalmortality.
192123Whiletherewerenoneonatal
or perinatal deaths reported by Landon et al
21 and in
the intervention group in Crowther et al,
19 five such
events occurred in the control group of Crowther et
al
19 (table 5). This difference was not significant
(P=0.07). In the study by O’Sullivan et al,
23 perinatal
mortality was 4% in the intervention group and 5% in
theconrolgroup(table 5).Againthedifferencewasnot
significant. Results were not pooled because of high
heterogeneity (P=0.099; I
2=63.3%) (fig 3).
The number of large for gestational age infants was
significantly lower in the treatment groups than in the
usualcaregroupsinfourstudies(table 5).
17192122Data
from these studies were also included in a meta-analy-
sis, which showed a significant reduction with specific
treatment for gestational diabetes mellitus (0.48, 0.38
to 0.62; fig 3). Macrosomia was also significantly
reduced in groups with specific treatment (0.38, 0.30
to 0.49). The number of small for gestational age
infants did not differ significantly between groups
(table 5 and fig 3).
Results from Crowther et al
19 and Landon et al
21 on
the number of babies with neonatal hypoglycaemia
treated with a glucose infusion could not be pooled in
meta-analyses because of heterogeneity (P=0.125;
I
2=57.6%). While in the study of Crowther et al
19
these events occurred more often in the intervention
group,inLandonetal
21theyoccurredlessoften(fig3).
The meta-analysis on birth trauma, which included
data from Crowther et al
19 and Landon et al,
21 showed
alowernumberofsucheventsintheinterventiongroup
than in the usual care group, but the difference was not
significant (0.39, 0.13 to 1.15; P=0.088; fig 3). Three
trialsprovided dataonthe numberofnewbornsrequir-
ing admission to a neonatal intensive care unit.
172122 In
each of these studies, a smaller proportion of infants
from mothers in the specific treatment group had to be
Table 3 |Risk of bias in included trials of treatment for gestational diabetes mellitus
Randomisation
adequate
Concealment of
allocation adequate
Blinding
ITT analyses* Further aspects
Potential for
study bias Patients Caregivers
End point
assessment
Study pool A: specific treatment v usual care
Bonomo 2005
17 Unclear Unclear No No Unclear No — High
Crowther 2005
18-20 Yes Yes Yes/no† Yes/no† Unclear Yes — Low
Landon 2009
21 Yes Yes Yes/no† Yes/no† Yes/unclear No — Low
Langer 1989
22 Unclear Unclear No No Unclear Yes — High
O’Sullivan 1966
23 Unclear Unclear No No Unclear Yes Patient flow not transparent High
Study pool B: intensive v less intensive treatment
Bancroft 2000
24,25 Yes Yes No Yes Unclear Yes Patient flow not transparent.
Pilot study aimed at feasibility
High
Bevier 1999
26 Unclear Unclear No No Unclear No Patient flow not transparent High
Bung 1991
27-29 Unclear Unclear No No Unclear No Patient flow not transparent High
Elnour 2008
30 Unclear Unclear No No Unclear No — High
Garner 1997
31-33 Yes Unclear No Unclear Unclear Yes Pilot study aimed at feasibility High
Homko 2002
34 Unclear Unclear No No Unclear Yes Patient flow not transparent High
Homko 2007
35 Unclear Unclear No No Unclear No Patient flow not transparent High
Kestilä 2007
36 Unclear Unclear No No Unclear Yes Patient flow not transparent High
Nachum 1999
37 Yes Yes No No No Yes — Low
Persson 1985
38 Unclear Unclear No No Unclear Unclear — High
Rae 2000
39 Unclear Yes Yes Yes Unclear Unclear Patient flow not transparent Low
Rey 1997
40 Yes Unclear No No Unclear Yes Patient flow not transparent High
Rossi 2000
41 Unclear Unclear No Yes Yes No Patient flow not transparent High
*Analyses considered as ITT (intention to treat) only if women were analysed in group to which they were randomised (regardless of actual treatment) and if all women randomised were
included in analyses.
†Women and care givers in control group but not in intervention group were blinded for results of glucose challenge test and oral glucose tolerance test.
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none was the difference significant. For this outcome,
we performed a pooled analysis and found that the
lower risk for babies of mothers with specific treatment
was not significant (0.73, 0.50 to 1.06; P=0.098; fig 3).
Crowther et al reported a combined end point,
which consisted of any of perinatal death, shoulder
dystocia, bone fracture, or nerve palsy.
19 Such compli-
cations were seen in 1% of all babies from mothers in
the intervention group and 4% of babies born to
mothersintheusualcaregroup(P=0.01fordifference).
Landon et al also reported a composite neonatal
outcome, including stillbirth, neonatal death, hypo-
glycaemia, hyperbilirubinaemia, raised C peptide
concentration in cord blood, and birth trauma, as the
designated primary end point.
21 This outcome
occurred in 32% of babies from mothers with specific
treatmentand37%ofbabiesfrommothersintheusual
care group (P=0.14 for difference).
No adverse effects from treatment were reported.
No trials reported on long term effects in the children.
Intensive v less intensive specific treatment: pool B
Tables 6 and 7 show results from individual studies.
None of the trials reported any maternal deaths. More
intensive treatment had no significant effects on the
incidence of caesarean section (1.04, 0.80 to 1.34;
fig 4). Five trials provided information on pre-
eclampsia.
2630343539 Because of the high heterogeneity
(P=0.116; I
2=46.1%) we did not perform a combined
analysis(fig4).Thedifferencebetweenthecomparison
groupsreachedsignificanceinonlyonetrial
30(table 6).
The pooled estimate showed a significant reduction in
shoulderdystociainwomenwithintensifiedtreatment
(0.31, 0.14 to 0.70; fig 4).
Onlyonetrialprovidedinformationonthedevelop-
ment of diabetes mellitus later in life.
2425 While no
women in the intensified treatment group developed
diabetes, this was the case for two women (7%) in the
control group. The difference was not significant. It
remains unclear how long after giving birth the
womenweretested.Asforadverseeventswithintensi-
fied treatment of gestational diabetes, only two studies
reported on maternal hypoglycaemia. In the trial by
Bung et al no woman experienced a hypoglycaemic
episode.
27-29 In the study by Nachum et al, one
woman (0.7%) in each of the comparison groups
experienced serious hypoglycaemia.
37 We found no
informationonpossibleadverseeffectsoffalsepositive
or false negative test results and labelling and on beha-
vioural changes postpartum.
Eight studies reported on perinatal
mortality,
242531-3840 with four perinatal deaths in 1380
pregnant women. The pooled estimate did not show a
significant difference between intensified and less
intensified treatment (0.96, 0.19 to 4.79; fig 5).
We carried out a meta-analysis for the results on
macrosomia and on babies with a birth weight at or
above the 90th centile (large for gestational age) but
could not give a pooled estimate because of the high
degreeofheterogeneity(P=0.166,I
2=31.5%formacro-
somia; P=0.021,I
2=52.4% forlarge forgestational age)
(fig 5).
The risk of babies with birth weights at or below the
10th centile (small for gestational age) was not signifi-
cantlydifferentbetweenthe groups(0.85,0.50 to1.44;
fig 5). Information on birth weight was available from
all but two studies
3041; in only one study
26 was it signif-
icantly lower in babies from women receiving intensi-
fied treatment (table 7).
Table 4 |Maternal outcomes in study pool A: specific treatment versus usual care
Maternal
mortality*
Shoulder
dystocia
Caesarean
section Pre-eclampsia
Diabetes mellitus
later in life
No (%) P value No (%) P value No (%) P value No (%) P value No (%) P value
Bonomo 2005
17
Intervention NA
NA
NA
NA
44 (29)
NA
NA
NA
NA
NA
Control NA NA 42 (28) NA NA
Crowther 2005
18-20
Intervention 0 (0)
NA
7( 1 )
0.08
152 (31)
0.73
NA†
NA
NA
NA
Control 0 (0) 16 (3) 164 (32) NA† NA
Landon 2009
21
Intervention ‡ NA
NA
7( 2 )
0.02
128 (27)
0.02
12 (3)
0.02
NA
NA
Control‡ NA 18 (4) 154 (34) 25 (6) NA
Langer 1989
22
Intervention 0 (0)
NA
NA
NA
9( 1 5 )
NA
NA
NA
NA
NA
Control 0 (0) NA 11 (17) NA NA
O’Sullivan 1966
23
Intervention 0 (0)
NA
NA
NA
NA
NA
NA
NA
107 (35)
NS
Control 0 (0) NA NA NA 110 (36)
NA=not applicable/not available; NS=not significant.
*Assumed to be zero in those studies that included all randomised women in analyses but not specifically reported.
†Pre-eclampsia defined as blood pressure ≥140/90 mm Hg on two occasions more than four hours apart; corresponds to pregnancy induced
hypertension rather than pre-eclampsia.
‡n=476 in intervention group, 455 in control group.
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palsy and bone fracture).
31-3437 A pooled analysis
showed no significant difference between the effects
of intensified and less intensified treatment (0.71, 0.16
to 3.17; fig 5). We found no information on neonatal
hypoglycaemia necessitating glucose infusion or on
the necessity of breathing support in babies with
respiratorydistresssyndrome.Insufficientdataonpos-
sible long term effects for the children were available.
Adverse effects from treatment were not reported.
Table 7 gives results on gestational age at delivery.
None of the studies that reported on this outcome
found significant differences between the comparison
groups.
DISCUSSION
Main findings
In this systematic review we found that shoulder dys-
tocia is reduced significantly in women treated for
gestational diabetes. Women who received specific
treatment for gestational diabetes also had fewer
macrosomic babies or babies with a birth weight at or
above the 90th centile. Specific treatment had no sig-
nificanteffectsonthenumberofbabiessmallforgesta-
tionalageoronperinatalorneonataldeath,
1921though
perinatal death was much more common in one older
study,
23probablyreflectingtheadvancesinpregnancy
and neonatal care from the 1960s to today.
We included data from randomised controlled trials
that looked at specific treatment compared with usual
care (study pool A) from five studies. Within this pool
the studies by Crowther et al
19 and Landon et al
21 had
the largest number of women included and had a low
risk of bias.
Crowther et al reported a significant reduction of a
combined end point consisting of perinatal death,
shoulder dystocia, bone fracture, or nerve palsy asso-
ciated with treatment for gestational diabetes.
19 The
combined end point in the study by Landon et al
including various perinatal outcomes (stillbirth,
neonatal death, hypoglycaemia, hyperbilirubinaemia,
raised concentration of C peptide in cord blood, and
birth trauma) was not significantly different between
treated and untreated women.
21
All studies in pool A recruited women with gesta-
tional diabetes based on a two step strategy. In a first
stepwomenwere selectedby a positiveresultona glu-
cose challenge test (or risk factors). These women
underwent an oral glucose tolerance test and were
included in the studies if the result was positive.
Bonomo et al, however, included women with a posi-
tive result on a glucose challenge test but a negative
result on an oral glucose tolerance test.
17
Results from randomised controlled trials that com-
pared different intensities of treatment for gestational
diabetes (study pool B) showed a significant reduction
in risk for shoulder dystocia with more intense treat-
ment. There were only four perinatal deaths in 1380
pregnancies.Thereductioninmacrosomiawasnotsig-
nificant. Results from study pool B were comparable
with those from pool A for the end points of small for
gestational age and major maternal complications.
Basedontheresultsweconcludedthatspecifictreat-
ment for gestational diabetes, mostly consisting of
treatment to lower blood glucose concentration,
alone or with special obstetric care, seems to lower
the risk of some perinatal or neonatal complications.
Wedidnotfindsufficientdatatodrawanyconclusions
on possible long term effects of treatment for gesta-
tional diabetes in the mothers or their children.
Strengths and limitations
To our knowledge this review is the most current
reportonthetopicandincludestherecentlypublished
trial by Landon et al.
21 It also benefits from a thorough
searchand assessmentof randomisedcontrolled trials,
performance of meta-analyses on a wide range of
maternal and neonatal outcomes, and the differentia-
tion between trials investigating specific treatment for
  Bonomo 200517
  Crowther 2005
18-20
  Landon 200921
  Langer 1989
22
Total
Test for heterogeneity: χ2=2.83, df=3, P=0.418, I2=0%
Test for overall effect: z=-1.71, P=0.087,τ=0
1.07 (0.65 to 1.76)
0.95 (0.73 to 1.24)
0.72 (0.54 to 0.95)
0.79 (0.30 to 2.06)
0.86 (0.72 to 1.02)
12.5
44.2
39.9
3.4
100.0
0.1 0.25 0.5 1 24 10
Caesarean section
Favours
intervention
Favours
control
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
42/150
164/510
154/455
11/63
371/1178
Control
44/150
152/490
128/476
9/63
333/1179
  Crowther 200518-20
  Landon 200921
Total
Test for heterogeneity: χ2=0.10, df=1, P=0.748, I2=0%
Test for overall effect: z=-2.85, P=0.004,τ=0
0.45 (0.18 to 1.09)
0.36 (0.15 to 0.88)
0.40 (0.21 to 0.75)
49.2
50.8
100.0
Shoulder dystocia
16/524
18/455
34/979
7/506
7/476
14/982
Intervention
Fig 2 | Maternal outcomes in pool A (DerSimonian and Laird random effects model)
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different intensities of treatment.
Theevidenceonbeneficialeffectsoftreatment,how-
ever,isstillunstable.Althoughweidentifiedmanystu-
dies investigating the effects of treatment, effects on
major end points important to patients remain uncer-
tain. These complications are infrequent and informa-
tionisavailablefromonlyafewoftheincludedstudies.
Two studies
1921 dominated the results, so the limita-
tionsofthesetrialsmustbeconsidered.InCrowtheret
  Crowther 2005
18-20
  Landon 2009
21
  O’Sullivan 1966
23
Test for heterogeneity: χ
2=2.72, df=1, P=0.099, I
2=63.3%
0.19 (0.04 to 0.96)
—
0.86 (0.41 to 1.84)
18.2
—
81.8
0.1 0.25 0.5 1 2 4 10
Perinatal and
neonatal mortality
Favours
intervention
Favours
control
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
5/524
0/455
15/308
Control
0/506
0/477
13/307
  Bonomo 200517
  Crowther 2005
18-20
  Landon 2009
21
  O’Sullivan 1966
23
Total
Test for heterogeneity: χ2=0.91, df=3, P=0.823, I
2=0%
Test for overall effect: z=-7.55, P<0.001, τ=0
0.39 (0.17 to 0.89)
0.55 (0.40 to 0.77)
0.45 (0.29 to 0.70)
0.22 (0.07 to 0.70)
0.48 (0.38 to 0.62)
Macrosomia
  Bonomo 200517
  Crowther 2005
18-20
  Landon 200921
  Langer 1989
22
Total
Test for heterogeneity: χ2=2.79, df=3, P=0.425, I
2=0%
Test for overall effect: z=-5.85, P<0.001, τ=0
Large for gestational age
21/150
115/524
66/454
15/63
217/1191
9/150
68/506
34/477
4/63
115/1196
8.9
55.2
31.4
4.4
100.0
0.47 (0.20 to 1.14)
0.40 (0.28 to 0.58)
0.37 (0.23 to 0.59)
0.30 (0.16 to 0.57)
0.38 (0.30 to 0.49)
16/150
110/524
65/454
40/308
231/1436
8/150
49/506
28/477
13/307
98/1440
8.1
47.8
29.2
15.0
100.0
1.49 (0.62 to 3.59)
0.89 (0.55 to 1.45)
1.20 (0.72 to 1.99)
1.55 (0.42 to 5.79)
1.10 (0.80 to 1.51)
  Bonomo 200517
  Crowther 2005
18-20
  Landon 2009
21
  Langer 198922
Total
Test for heterogeneity: χ2=1.54, df=3, P=0.672, I2=0%
Test for overall effect: z=0.61, P=0.543, τ=0
Small for gestational age
9/150
38/524
29/455
4/63
80/1192
13/150
33/506
36/477
6/63
88/1196
12.8
42.7
38.8
5.7
100.0
0.23 (0.03 to 1.64)
0.49 (0.13 to 1.81)
0.39 (0.13 to 1.15)
  Crowther 200518-20
  Landon 200921
Total
Test for heterogeneity: χ2=0.39, df=1, P=0.533, I2=0%
Test for overall effect: z=-1.71, P=0.088
Birth trauma
3/524
6/455
9/979
0/506
3/476
3/982
30.9
69.1
100.0
Intervention
0.70 (0.22 to 2.27)
0.75 (0.49 to 1.15)
0.54 (0.15 to 1.95)
0.73 (0.50 to 1.06)
  Bonomo 200517
  Landon 200921
  Langer 1989
22
Total
Test for heterogeneity: χ2=0.23, df=2, P=0.893, I
2=0%
Test for overall effect: z=-1.65, P=0.098, τ=0
Neonatal intensive care
7/150
53/455
7/63
67/668
5/150
43/477
4/63
52/690
10.6
80.6
8.8
100.0
1.37 (0.82 to 2.30)
0.76 (0.44 to 1.31)
  Crowther 200518-20
  Landon 2009
21
Test for heterogeneity: χ2=2.36, df=1, P=0.125, I2=57.6%
Neonatal hypoglycaemia with glucose infusion
27/524
31/455
35/506
25/475
51.0
49.0
Fig 3 | Neonatal outcomes in pool A (DerSimonian and Laird random effects model, except for perinatal and neonatal morality
and birth trauma, which use Peto fixed effects model)
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19 women in the control group had gestational dia-
betes but they and their perinatal care providers were
told that they did not have it. Women in the inter-
vention group were not blinded. This can be seen as a
possible bias leading to undertreatment in the control
group or overtreatment in the intervention group (or
both).Inusualcare“telling”ispartoftheintervention,
sothisislikelytoreflectwhathappenswhenlabellinga
pregnant woman with the diagnosis of gestational dia-
betes. Induction of labour and transfer of newborns to
a neonatal nursery were higher in the intervention
group. We regarded these interventions as part of the
specific care for gestational diabetes. It is unclear
whether these interventions were responsible for the
improved neonatal outcomes or whether they were
overtreatment (and a harm) induced by labelling.
Table 6 |Maternal outcomes in study pool B: intensive versus less intensive treatment
Maternal
mortality*
Shoulder
dystocia
Caesarean
section Pre-eclampsia
Diabetes mellitus
later in life
No (%) P value No (%) P value No (%) P value No (%) P value No (%) P value
Bancroft 2000
24 25
Intervention 0 (0)
NA
0( 0 )
NA
10 (31)
NS
NA
NA
0( 0 ) †
NS
Control 0 (0) 1 (3) 11 (31) NA 2 (7)†
Bevier 1999
26
Intervention NA
NA
1( 3 )
NS
5( 1 4 )
NA
2( 6 )
NS
NA
NA
Control NA 2 (5) 12 (25) 1 (2) NA
Bung 1991
27-29
Intervention NA
NA
NA
NA
3( 1 8 )
NA
NA
NA
NA
NA
Control NA NA 2 (12) NA NA
Elnour 2008
30
Intervention NA
NA
2( 2 )
0.061
7( 7 )
0.028
5( 5 )
0.014
NA
NA
Control NA 6 (9) 12 (18) 11 (17) NA
Garner 1997
31-33
Intervention NA
NA
NA
NA
NA (20)
0.861
NA
NA
NA
NA
Control NA NA NA (19) NA NA
Homko 2002
34
Intervention NA
NA
NA
NA
11 (36)
NS
0( 0 )
NS
NA
NA
Control NA NA 5 (19) 2 (7) NA
Homko 2007
35
Intervention NA
NA
NA
NA
22 (69)
0.53
9( 2 8 ) ‡
NS
NA
NA
Control NA NA 10 (40) 5 (20)‡ NA
Kestilä 2007
36
Intervention 0 (0)
NA
NA
NA
NA (22)
0.47
NA
NS
NA
NA
Control 0 (0) NA NA (22) NA NA
Nachum 1999
37
Intervention 0 (0)
NA
NA
NA
39 (28)
NS
NA
NA
NA
NA
Control 0 (0) NA 38 (28) NA NA
Persson 1985
38
Intervention 0 (0)
NA
NA
NA
NA
NA
NA
NS
NA
NA
Control 0 (0) NA NA NA NA
Rae 2000
39
Intervention NA
NA
0( 0 )
0.095
26 (41)
NA
14 (22)
0.838
NA
NA
Control NA 3 (6) 19 (35) 13 (22) NA
Rey 1997
40
Intervention 1§ NA
NA
1( 1 )
NS
24 (21)
NA
NA
NA
NA
NA
Intervention 2§ NA 0 (0) 26 (23) NA NA
Control 1§ NA
NA
0( 0 )
<0.05
14 (24)
NA
NA
NA
NA
NA
Control 2§ NA 4 (7) 14 (25) NA NA
Rossi 2000
41
Intervention NA
NA
NA
NA
17 (23)
NS
NA
NA
NA
NA
Control NA NA 17 (25) NA NA
NA=not applicable/not available; NS=not significant.
*Assumed to be zero in those studies that included all randomised women in analyses but not specifically reported.
†Two additional women (7%) in intervention group and three in control group (11%) developed glucose intolerance P=NS. Analyses included only 56
of 68 randomised women.
‡Sum of pregnancy associated hypertension and pre-eclampsia.
§Blood glucose one hour after standardised breakfast; group 1 <7.8 mmol/l, group 2 ≥7.8 mmol/l.
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combinedendpoint.
19Thoughthisendpointhasbeen
criticised
44becauseitdependsheavilyonshoulderdys-
tocia, a subjective end point, we accepted it as valid. A
sensitivityanalysisshowedthatevenwithoutinclusion
of shoulder dystocia, the rates would be significantly
different (data not shown).
We did not consider the combined end point in the
study by Landon et al
21 as valid because it included
surrogate end points like concentrations of C peptide
in cord blood. Although we considered the risk of bias
in their study in general to be low, for some end points
we thought the risk of bias was higher because not all
randomised women were included in the analyses.
Study pool B contained trials that tested a broad
spectrumofdifferentinterventions,includingdifferent
formsofbloodglucosemonitoringandtreatmentswith
oralantidiabeticdrugs.Also,theselectioncriteriawere
heterogeneous between studies. This heterogeneity,
and the fact that most of the trials from pool B were at
high risk of bias, makes it more difficult to draw sound
inferences. It is reassuring, however, that the results
from both study pools were concordant.
Anotherlimitationconcernsthetransferabilityofthe
results.Asmostoftheincludedstudieswereconducted
inNorthAmerica,Europe,andAustralianotallethnic
groups were sufficiently represented. It remains
unclear if the results found are applicable to women
from, for example, South East Asia and China.
Our conclusions are also somewhat restricted as the
included trials did not explicitly investigate the harms
of treatment. Crowther et al reported that women in
the intervention group did not worry more or less
than women in the control group but did significantly
betterinregardtodepressionafterbirth,physicalfunc-
tioning, and health state utility.
19 But these analyses
have a high risk of bias because a high percentage of
women were not included in the analyses. Rates of
  Bancroft 200024 25
  Bevier 199926
  Bung 1991
27-29
  Elnour 200830
  Garner 199731-33
  Homko 2002
34
  Homko 200735
  Kestila 2007
36
  Nachum 199937
  Rae 200039
  Rey 1997 >7.8 mmol/l
40
  Rey 1997 <7.8 mmol/l40
  Rossi 200041
Total
Test for heterogeneity: χ2=14.37, df=12, P=0.277, I
2=16.5%
Test for overall effect: z=0.26, P=0.791,τ=0.189
1.03 (0.37 to 2.89)
0.50 (0.16 to 1.58)
1.68 (0.25 to 11.27)
0.34 (0.13 to 0.92)
1.09 (0.61 to 1.93)
2.42 (0.72 to 8.18)
3.48 (1.23 to 9.85)
1.04 (0.34 to 3.14)
1.02 (0.60 to 1.72)
1.29 (0.61 to 2.74)
0.89 (0.38 to 2.09)
0.93 (0.50 to 1.75)
0.91 (0.42 to 1.97)
1.04 (0.80 to 1.34)
5.5
4.5
1.7
5.9
14.1
4.0
5.4
4.8
15.8
9.4
7.6
12.3
9.0
100.0
0.1 0.25 0.5 1 24 10
Caesarean section
Favours
intervention
Favours
control
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
11/36
12/48
2/21
12/66
28/150
5/27
10/29
8/37
38/136
19/54
14/55
26/115
17/68
202/842
Control
10/32
5/35
3/20
7/99
30/150
11/31
22/34
8/36
39/138
26/63
14/60
24/112
17/73
216/883
  Bancroft 200024 25
  Bevier 199926
  Elnour 2008
30
  Rae 2000
39
  Rey 1997 >7.8 mmol/l
40
  Rey 1997 <7.8 mmol/l40
Total
Test for heterogeneity: χ2=3.81, df=5, P=0.577, I
2=0%
Test for overall effect: z=-2.82, P=0.005
0.41 (0.02 to 6.65)
0.69 (0.07 to 7.02)
0.22 (0.05 to 0.93)
0.18 (0.02 to 1.33)
0.17 (0.03 to 1.04)
2.80 (0.17 to 45.11)
0.31 (0.14 to 0.70)
2.85 (0.25 to 32.73)
0.27 (0.09 to 0.81)
0.16 (0.01 to 3.53)
1.73 (0.51 to 5.90)
0.90 (0.38 to 2.13)
8.6
12.5
32.2
17.0
21.1
8.7
100.0
Shoulder dystocia
1/36
2/48
6/66
3/54
4/55
0/115
16/374
0/32
1/35
2/99
0/63
0/60
1/112
4/401
  Bevier 199926
  Elnour 2008
30
  Homko 2002
34
  Homko 200735
  Rae 2000
39
Test for heterogeneity: χ
2=7.42, df=4, P=0.116, I
2=46.1%
Pre-eclampsia
1/48
11/66
2/27
5/29
13/54
2/35
5/99
0/31
9/34
14/63
10.0
26.7
6.8
24.3
32.3
Intervention
Fig 4 | Maternal outcomes in pool B (DerSimonian and Laird random effects model, except for shoulder dystocia, which uses
Peto fixed effects model)
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24 25
  Garner 199731-33
  Homko 200234
  Homko 2007
35
  Kestila 200736
  Nachum 1999
37
  Persson 198538
  Rey 1997 >7.8 mmol/l
40
  Rey 1997 <7.8 mmol/l
40
Total
Test for heterogeneity: χ2=1.05, df=2, P=0.591, I
2=0%
Test for overall effect: z=-0.05, P=0.959
—
—
0.87 (0.05 to 14.33)
—
—
0.36 (0.02 to 5.80)
—
—
2.80 (0.17 to 45.11)
0.96 (0.19 to 4.79)
—
—
32.9
—
—
33.6
—
—
33.5
100.0
0.1 0.25 0.5 1 2 4 10
Perinatal and
neonatal mortality
Favours
intervention
Favours
control
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
0/36
0/150
1/27
0/29
0/37
1/136
0/105
0/55
0/115
2/690
Control
0/32
0/150
1/31
0/34
0/36
0/138
0/97
0/60
1/112
2/690
  Bevier 199926
  Bung 1991
27-29
  Elnour 2008
30
  Garner 1997
31-33
  Kestila 200736
  Nachum 1999
37
  Rae 200039
  Rey 1997 >7.8 mmol/l
40
  Rey 1997 <7.8 mmol/l
40
Test for heterogeneity: χ
2=11.69, df=8, P=0.166, I
2=31.5%
0.09 (0.01 to 0.72)
2.38 (0.38 to 14.70)
0.39 (0.17 to 0.91)
0.83 (0.46 to 1.51)
1.42 (0.29 to 6.83)
0.80 (0.43 to 1.50)
1.73 (0.60 to 5.03)
0.71 (0.27 to 1.86)
1.14 (0.47 to 2.81)
1.38 (0.44 to 4.36)
0.09 (0.01 to 0.72)
0.34 (0.14 to 0.83)
0.67 (0.18 to 2.52)
3.12 (0.76 to 12.87)
0.82 (0.48 to 1.39)
0.83 (0.36 to 1.93)
1.27 (0.57 to 2.84)
0.34 (0.13 to 0.88)
2.40 (0.80 to 7.13)
0.57 (0.22 to 1.51)
3.2
4.1
13.8
20.1
5.3
19.3
10.0
11.4
12.7
Macrosomia
12/48
2/21
16/66
28/150
3/37
26/136
6/58
11/55
10/115
1/35
4/20
11/99
24/150
4/36
22/138
11/66
9/60
11/112
  Bancroft 200024 25
  Bevier 199926
  Elnour 200830
  Homko 2002
34
  Homko 2007
35
  Nachum 199937
  Persson 198538
  Rae 200039
  Rey 1997 >7.8 mmol/l40
  Rey 1997 <7.8 mmol/l
40
  Rossi 2000
41
Test for heterogeneity: χ
2=21.01, df=10, P=0.021, I
2=52.4%
Large for gestational age
7/36
12/48
15/66
6/27
3/29
41/136
14/105
14/58
17/55
5/115
12/68
8/32
1/35
9/99
5/31
9/34
36/138
11/97
19/66
8/60
11/112
8/73
8.0
3.5
10.4
6.8
6.2
14.7
10.9
11.4
9.9
8.5
9.7
2.16 (0.34 to 13.65)
0.69 (0.28 to 1.67)
0.55 (0.16 to 1.92)
0.15 (0.01 to 2.95)
0.60 (0.10 to 3.72)
1.51 (0.55 to 4.12)
0.85 (0.50 to 1.44)
  Bevier 199926
  Elnour 200830
  Nachum 199937
  Persson 1985
38
  Rey 1997 >7.8 mmol/l
40
  Rey 1997 <7.8 mmol/l
40
Total
Test for heterogeneity: χ2=4.38, df=5, P=0.496, I
2=0%
Test for overall effect: z=-0.60, P=0.545, τ=0
Small for gestational age
2/48
11/66
7/136
3/105
3/55
7/115
33/525
3/35
12/99
4/138
0/97
2/60
10/112
31/541
8.1
35.3
17.7
3.1
8.3
27.5
100.0
—
0.87 (0.05 to 14.33)
0.66 (0.11 to 3.84)
0.71 (0.16 to 3.17)
  Garner 199731-33
  Homko 200234
  Nachum 199937
Total
Test for heterogeneity: χ2=0.03, df=1, P=0.869, I2=0%
Test for overall effect: z=-0.45, P=0.654
Birth trauma
0/150
1/27
3/136
4/313
0/150
1/31
2/138
3/319
—
28.4
71.6
100.0
Intervention
Fig 5 | Neonatal outcomes in pool B (DerSimonian and Laird random effects model, except for perinatal and neonatal morality
and birth trauma, which use Peto fixed effects model)
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age babies, and gestational age at birth were not signif-
icantly different between interventions so no indica-
tion of labelling or other harmful effects was found
for these outcomes.
Eventhoughinternationalbodiesandexpertsrecog-
nise that women with gestational diabetes have an
increased risk of developing diabetes later in life, only
two out of the 18 studies included in our systematic
review reported on this outcome. We also found no
information on possible behavioural changes in
women to prevent diabetes and insufficient data on
long term outcomes in the children.
The strongest evidence for beneficial effects of treat-
ment comes from studies in which insulin was the sole
pharmacological agent used for lowering blood glu-
cose. Our systematic review did not compare insulin
with oral antidiabetic agents. A recent systematic
review from the Agency for Healthcare Research and
Qualityfoundthatmaternalglucoseconcentrationsdo
not differ substantially in those treated with insulin
compared with insulin analogues or oral agents.
45
The authors also state that their conclusions were wea-
kened by the low number of available studies and the
paucity of outcomes reported.
Comparison with other reviews
In 2008 the US Preventive Services Task Force
(USPSTF) published a report on screening for gesta-
tional diabetes.
4 In that review Hillier et al included
eight randomised controlled trials investigating the
effects of specific treatment for gestational diabetes.
Of these, four studies
19232437 were also included in
oursystematicreview.Weexcludedtheotherfourstu-
dies because they did not fulfil our inclusion criterion
concerning a difference in the intensity of
treatment.
46-49 The task force did not accept shoulder
dystocia as a valid end point and concluded that cur-
rent evidence was insufficient to assess the balance of
benefits and harms of screening for gestational dia-
betes.Nometa-analyseswereperformedinthisreport.
In 2008 the National Institute for Health and Clini-
cal Excellence (NICE) issued new guidelines for the
management of pregnant women with diabetes
mellitus
50 and for the care of healthy pregnant
women.
8 These guidelines recommend a two step
screeningstrategyforgestationaldiabetesinallhealthy
pregnant women on the basis of risk factors and a 75 g
oral glucose tolerance test. For diagnosis the WHO
cut-off values
9 are recommended.
Does the evidence support screening for gestational
diabetes?
Weconsiderthereisabenefitwithintensivetreatment,
including daily self measurement, diet, and, for some
women, insulin and additional obstetric intervention.
Compared with routine care this management is asso-
ciated with a reduction in the incidence of shoulder
dystocia and macrosomia. Currently there is less
robust evidence that treatment for gestational diabetes
leads to a reduction in more serious maternal or peri-
natal complications.
This benefit, although limited, might be seen as a
justification for screening. It is not known if screening
hasharmsserious enoughto counterbalancethe possi-
ble benefits of treatment. Effects can be fully judged
only by screening trials, which follow up women with
negative screening results. As there are no reliable
screening studies available
4850and we could not iden-
tify ongoing studies, we do not expect the evidence
base to change much in the foreseeable future.
In our opinion proposals for screening for gesta-
tionaldiabeteshavetotakeintoaccountthatsomeevi-
dence of benefit of treatment is derived from trials for
which women were selected by a two step strategy
combining a glucose challenge test (or screening for
risk factors, or both) and an oral glucose tolerance test.
Currently an international consensus for screening
of gestational diabetes is being developed
51 based on
the risk associations reported in the HAPO study—an
observational study describing the “natural” correla-
tionbetweenbloodglucoseconcentrationinmid-preg-
nancy measured by a 75 g two hour oral glucose
tolerance test and a broad range of outcomes.
2
Women and caregivers were blinded to the results of
the tolerance tests. A consensus based on the HAPO
dataassumesthatthebenefitsseenforwomenincluded
in intervention trialscan be transferredto womenwith
a diagnosis of gestational diabetes deduced from the
risk associations seen in HAPO.
51
We think that the transferability of benefits cannot
be taken for granted. For example, while women in all
the interventional studies in pool A were selected in a
two step process consisting of a 50 g glucose challenge
test(orscreeningforriskfactors,orboth)andasecond
75 g or 100 g oral glucose tolerance test, women in
HAPO
2 underwent only a one step 75 g oral glucose
tolerance test. Transferability is also hampered by the
fact that the studies applied different inclusion and
exclusion criteria, recruited different ethnic groups,
and defined outcomes differently. An indication that
this might have an impact is that, although the mean
fasting blood glucose concentrations in the studies of
Crowther et al
19 and Landon et al
21 were similar
(86.5 mg/dl (4.76 mmol/l) and 86.6 mg/dl
(4.77 mmol/l), respectively) and not that different
WHAT IS ALREADY KNOWN ON THIS TOPIC
Specifictreatmentofwomenwithgestational diabetesmellitusisrecommendedtolowerthe
risk of adverse pregnancy outcomes in the mother and baby
It is unclear which outcomes can be influenced and which women with gestational diabetes
and their babies will benefit from treatment, depending on the mother’sd e g r e eo f
carbohydrate intolerance
WHAT THIS STUDY ADDS
Treatmentofgestationaldiabetesseemstohavebeneficialeffects onsomecomplications of
pregnancy
The evidence of benefit is derived from trials for which women were selected by a two step
strategy combining a glucose challenge test or screening for risk factors, or both, and an oral
glucose tolerance test
RESEARCH
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2 (80.9 mg/dl (4.46 mmol/l)), the
incidenceoflargeforgestationalagebabiesinthecon-
trol groups was rather different (22%,
19 15%,
21 9.5%
2).
Studies comparing different screening strategies for
gestational diabetes are needed to allow for a proper
assessmentofthebalanceofbenefitandharmsofscreen-
ing.Pregnantwomenshouldbeinformedaboutthepos-
sible benefits as well as the uncertainties concerning
screening. Recommendations for screening strategies
should mirror the selection strategies of women for
whom a benefit of treatment has been shown.
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